Drug Profile
Acetylcysteine - Zambon
Alternative Names: Fluimucil; Flumil; N-acetylcysteine - Zambon; NAC - Zambon; NSC 111180; RinofluimucilLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Zambon Company SpA
- Developer Elder Pharmaceuticals; Inpharzam Ricerche S.A.; Sermmitr; Zambon Company SpA
- Class Anti-inflammatories; Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
- Mechanism of Action Antioxidants; Free radical inhibitors; Glutamate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease; Common cold; Poisoning; Respiratory tract disorders
- Discontinued HIV infections; Pulmonary fibrosis; Renal failure
Most Recent Events
- 05 Feb 2021 Zambon completes a phase III trial for Respiratory tract disorers in China (IV, Infusion) (NCT03843541)
- 18 Jan 2020 Zambon SpA completes a phase I trial in Respiratory tract disorders (In volunteers) in China (IV, Infusion) (NCT03881163)
- 11 Nov 2019 Zambon SpA initiates a phase I trial in Respiratory tract disorders (In volunteers) in China (IV, Infusion) (NCT03881163)